News Takeda's Ninlaro fails phase 3 amyloidosis trial Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints.
News Takeda’s myeloma drug Ninlaro approved in Europe Takeda has gained European Union approval of its multiple myeloma drug Ninlaro for second line use – joining a wave of new treatments for the incurable condition.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.